Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Telomir Pharmaceuticals logo
$0.44 +0.01 (+3.05%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Telomir Pharmaceuticals Stock (NASDAQ:TELO)

Advanced

Key Stats

Today's Range
$0.44
▼
$0.44
50-Day Range
$0.42
▼
$1.25
52-Week Range
$0.40
▼
$1.58
Volume
23,092 shs
Average Volume
123,171 shs
Market Capitalization
$32.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Hold

Company Overview

Telomir Pharmaceuticals is a biotechnology company focused on developing treatments based on research into telomeres, the protective structures at the ends of chromosomes, and cellular metal regulation.

Its lead investigational candidate, Telomir-1, is a small molecule being studied for its potential to affect telomere biology. The company has described possible applications in cancer and age-related conditions; these uses remain under investigation.

Telomir-1 is an experimental product, not an approved medicine. The company’s work is at an early development stage, and its research has not established the candidate’s safety or effectiveness as a treatment.

AI Generated. May Contain Errors.

Telomir Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

TELO MarketRank™: 
1.997866097625 of 5 stars

Telomir Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 662nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Telomir Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Telomir Pharmaceuticals has a consensus price target of $4.00, representing about 845.4% upside from its current price of $0.42.

  • Amount of Analyst Coverage

    Telomir Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Telomir Pharmaceuticals' stock forecast and price target.
  • Percentage of Shares Shorted

    1.22% of the float of Telomir Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Telomir Pharmaceuticals has recently decreased by 2.53%, indicating that investor sentiment is improving.
  • Dividend Yield

    Telomir Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Telomir Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Telomir Pharmaceuticals has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.36% of the stock of Telomir Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Telomir Pharmaceuticals has minimal institutional ownership at this time.

  • Read more about Telomir Pharmaceuticals' insider trading history.
Receive TELO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TELO Stock News Headlines

This Could Be the Biggest Monetary Shift in 50 Years
The U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.tc pixel
See More Headlines

TELO Stock Analysis - Frequently Asked Questions

Telomir Pharmaceuticals' stock was trading at $1.33 at the start of the year. Since then, TELO stock has decreased by 68.2% and is now trading at $0.4231.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) posted its quarterly earnings results on Friday, November, 6th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02.

Telomir Pharmaceuticals (TELO) raised $7 million in an IPO on Friday, February 9th 2024. The company issued 1,000,000 shares at $7.00 per share. Kingswood Investments acted as the underwriter for the IPO.

Top institutional shareholders of Telomir Pharmaceuticals include State Street Corp (0.08%).

Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/06/2026
Today
11/18/2026
Next Earnings (Estimated)
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:TELO
Previous Symbol
NASDAQ:TELO
CIK
1971532
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

High Price Target
$4.00
Low Price Target
$4.00
Potential Upside/Downside
+845.4%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$10.41 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-107.89%
Return on Assets
-94.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.58
Quick Ratio
19.58

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.06 per share
Price / Book
7.05

Miscellaneous

Outstanding Shares
73,680,000
Free Float
61,623,000
Market Cap
$31.17 million
Optionable
N/A
Beta
-0.19
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:TELO) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners